142 related articles for article (PubMed ID: 3315283)
1. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.
Pearson AD; Mills S; Amineddine HA; Long DR; Craft AW; Chessells JM
Cancer Chemother Pharmacol; 1987; 20(3):243-7. PubMed ID: 3315283
[TBL] [Abstract][Full Text] [Related]
2. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia.
Chessells JM; Leiper AD; Tiedemann K; Hardisty RM; Richards S
Arch Dis Child; 1987 Feb; 62(2):172-6. PubMed ID: 3469936
[TBL] [Abstract][Full Text] [Related]
3. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.
Pearson AD; Amineddine HA; Yule M; Mills S; Long DR; Craft AW; Chessells JM
Br J Cancer; 1991 Jul; 64(1):169-73. PubMed ID: 1854617
[TBL] [Abstract][Full Text] [Related]
4. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?
Pinkerton CR; Welshman SG; Glasgow JF; Bridges JM
Lancet; 1980 Nov; 2(8201):944-6. PubMed ID: 6107590
[TBL] [Abstract][Full Text] [Related]
5. Serum profiles of methotrexate after its administration in children with acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Bridges JM
Br J Cancer; 1982 Feb; 45(2):300-3. PubMed ID: 6949608
[No Abstract] [Full Text] [Related]
6. Modification of oral methotrexate absorption in children with leukemia.
Mahony MJ; Murphy MS; Wadsworth J; Mott MG
Cancer Chemother Pharmacol; 1984; 12(2):131-3. PubMed ID: 6583027
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate bioavailability after oral and intramuscular administration in children.
Teresi ME; Crom WR; Choi KE; Mirro J; Evans WE
J Pediatr; 1987 May; 110(5):788-92. PubMed ID: 3471936
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Kelly JG; Shanks RG; Bridges JM
Cancer Chemother Pharmacol; 1982 Dec; 10(1):36-9. PubMed ID: 6961972
[TBL] [Abstract][Full Text] [Related]
9. Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.
Kearney PJ; Light PA; Preece A; Mott MG
Cancer Chemother Pharmacol; 1979; 3(2):117-20. PubMed ID: 292536
[TBL] [Abstract][Full Text] [Related]
10. Improvement in treatment for children with acute lymphoblastic leukaemia. The Medical Research Council UKALL trials, 1972-84. Report to the Council by the Working Party on Leukaemia in Childhood.
Lancet; 1986 Feb; 1(8478):408-11. PubMed ID: 2868339
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate absorption in children with acute lymphoblastic leukemia.
Craft AW; Rankin A; Aherne W
Cancer Treat Rep; 1981; 65 Suppl 1():77-81. PubMed ID: 6948609
[TBL] [Abstract][Full Text] [Related]
12. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
Borsi JD; Moe PJ
Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of subcutaneous methotrexate.
Balis FM; Mirro J; Reaman GH; Evans WE; McCully C; Doherty KM; Murphy RF; Jeffries S; Poplack DG
J Clin Oncol; 1988 Dec; 6(12):1882-6. PubMed ID: 3199171
[TBL] [Abstract][Full Text] [Related]
14. Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia.
Pearson AD; Craft AW; Eastham EJ; Aherne GW; Littleton P; Pearson GL; Campbell AN
Cancer Chemother Pharmacol; 1985; 14(3):211-5. PubMed ID: 3858014
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral methotrexate in children.
Balis FM; Savitch JL; Bleyer WA
Cancer Res; 1983 May; 43(5):2342-5. PubMed ID: 6572562
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate and folate content of erythrocytes in patients receiving oral vs intramuscular therapy with methotrexate.
Kamen BA; Holcenberg JS; Turo K; Whitehead VM
J Pediatr; 1984 Jan; 104(1):131-3. PubMed ID: 6581287
[No Abstract] [Full Text] [Related]
18. Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance.
Crom WR; Glynn AM; Abromowitch M; Pui CH; Dodge R; Evans WE
Clin Pharmacol Ther; 1986 May; 39(5):592-7. PubMed ID: 3516513
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation.
Chessells JM; Cox TC; Kendall B; Cavanagh NP; Jannoun L; Richards S
Arch Dis Child; 1990 Apr; 65(4):416-22. PubMed ID: 2346334
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.
Evans WE; Crom WR; Abromowitch M; Dodge R; Look AT; Bowman WP; George SL; Pui CH
N Engl J Med; 1986 Feb; 314(8):471-7. PubMed ID: 3456079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
